116 related articles for article (PubMed ID: 38452907)
1. Preparation of etoposide liposomes for enhancing antitumor efficacy on small cell lung cancer and reducing hematotoxicity of drugs.
Huang R; Chen H; Pi D; He X; Yu C; Yu C
Eur J Pharm Biopharm; 2024 May; 198():114239. PubMed ID: 38452907
[TBL] [Abstract][Full Text] [Related]
2. Preparation of PEGylated nedaplatin liposomes with sustained release behavior for enhancing the antitumor efficacy of non-small cell lung cancer.
Tang J; Yang Z; Zhang Y; Huang R; Yu C; Yu C
Int J Pharm; 2023 Mar; 635():122708. PubMed ID: 36764415
[TBL] [Abstract][Full Text] [Related]
3. pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer.
Zhu R; Wang Q; Zhu Y; Wang Z; Zhang H; Wu B; Wu X; Wang S
Acta Biomater; 2016 Jan; 29():320-332. PubMed ID: 26485164
[TBL] [Abstract][Full Text] [Related]
4. A liposomal etoposide with a sustained drug release effectively alleviated the therapy-related leukemia.
Xiong Y; Xie L; Tang L; Xiao D; Shi W; Wang Y; Li Y; Han X; Ying X; Zheng Y
Int J Pharm; 2023 Nov; 646():123437. PubMed ID: 37741559
[TBL] [Abstract][Full Text] [Related]
5. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
6. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
[TBL] [Abstract][Full Text] [Related]
7. The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer.
Hansen LT; Lundin C; Spang-Thomsen M; Petersen LN; Helleday T
Int J Cancer; 2003 Jul; 105(4):472-9. PubMed ID: 12712436
[TBL] [Abstract][Full Text] [Related]
8. Preparation and evaluation of etoposide-loaded lipid-based nanosuspensions for high-dose treatment of lymphoma.
Yin X; Han L; Mu S; Mu W; Liang S; Wang T; Liu Y; Zhang N
Nanomedicine (Lond); 2019 Jun; 14(11):1403-1427. PubMed ID: 31180263
[No Abstract] [Full Text] [Related]
9. Biodistribution of etoposide via intratumoral chemotherapy with etoposide-loaded implants.
Wu C; Yi X; Xu R; Zhang M; Xu Y; Ma Y; Gao L; Zha Z
Drug Deliv; 2020 Dec; 27(1):974-982. PubMed ID: 32611260
[TBL] [Abstract][Full Text] [Related]
10. DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer.
Hansen LT; Lundin C; Helleday T; Poulsen HS; Sørensen CS; Petersen LN; Spang-Thomsen M
Lung Cancer; 2003 May; 40(2):157-64. PubMed ID: 12711116
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis.
Mascaux C; Paesmans M; Berghmans T; Branle F; Lafitte JJ; Lemaitre F; Meert AP; Vermylen P; Sculier JP;
Lung Cancer; 2000 Oct; 30(1):23-36. PubMed ID: 11008007
[TBL] [Abstract][Full Text] [Related]
12. Preparation, characterization and
Zare Kazemabadi F; Heydarinasab A; Akbarzadeh A; Ardjmand M
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3222-3230. PubMed ID: 31373225
[No Abstract] [Full Text] [Related]
13. Adenosine triphosphate (ATP) enhances the antitumor effect of etoposide (VP16) in lung cancer cells.
Hatta Y; Takahashi M; Enomoto Y; Takahashi N; Sawada U; Horie T
Oncol Rep; 2004 Nov; 12(5):1139-42. PubMed ID: 15492806
[TBL] [Abstract][Full Text] [Related]
14. Preparation, Characterization, and In Vitro Pharmacodynamics and Pharmacokinetics Evaluation of PEGylated Urolithin A Liposomes.
Yi S; Zhang C; Hu J; Meng Y; Chen L; Yu H; Li S; Wang G; Zheng G; Qiu Z
AAPS PharmSciTech; 2021 Jan; 22(1):26. PubMed ID: 33404864
[TBL] [Abstract][Full Text] [Related]
15. The in vitro sustained release profile and antitumor effect of etoposide-layered double hydroxide nanohybrids.
Qin L; Wang M; Zhu R; You S; Zhou P; Wang S
Int J Nanomedicine; 2013; 8():2053-64. PubMed ID: 23737669
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
[TBL] [Abstract][Full Text] [Related]
17. Preparation, Characterization, and Anti-Lung Cancer Activity of Tetrandrine-Loaded Stealth Liposomes.
Fang Z; Lin P; Gao R; Yang W; Zhou A; Yu W
Int J Nanomedicine; 2024; 19():787-803. PubMed ID: 38293606
[TBL] [Abstract][Full Text] [Related]
18. Effect of Tween-80 on cell killing by etoposide in human lung adenocarcinoma cells.
Tsujino I; Yamazaki T; Masutani M; Sawada U; Horie T
Cancer Chemother Pharmacol; 1999; 43(1):29-34. PubMed ID: 9923538
[TBL] [Abstract][Full Text] [Related]
19. Intracellular uptake of etoposide-loaded solid lipid nanoparticles induces an enhancing inhibitory effect on gastric cancer through mitochondria-mediated apoptosis pathway.
Wang J; Zhu R; Sun X; Zhu Y; Liu H; Wang SL
Int J Nanomedicine; 2014; 9():3987-98. PubMed ID: 25187702
[TBL] [Abstract][Full Text] [Related]
20. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
